GSK and SK biosciences COVID vaccine submitted for S Korea approval
GSK said that SK bioscience will also apply to the World Health Organization (WHO) for emergency use listing and seek authorisations at individual regulatory agencies around the world.
GlaxoSmithKline's (GSK) COVID-19 vaccine candidate developed with SK bioscience has been submitted for regulatory approval in South Korea after positive positive Phase III clinical data, the British drugmaker said on Friday. GSK said that SK bioscience will also apply to the World Health Organization (WHO) for emergency use listing and seek authorisations at individual regulatory agencies around the world. The company said an extended clinical trial is planned to test the vaccine's effectiveness against the Omicron variant of the virus
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!